News

Quantum Genomics, a biopharmaceutical company specializing in the development of first-in-class drugs directly targeting the brain to treat complex/resistant hypertension, has announced…
Read More...

Jacobio Pharma (1167.HK) has received the Investigational New Drug (the "IND") approval of the combination therapy of KRAS G12C inhibitor JAB-21822 and Cetuximab injection from the…
Read More...

NJ Biopharmaceuticals LLC an expert provider of chemistry and biopharmaceutical services specializing in bioconjugation, custom synthesis, flow chemistry, and process development has…
Read More...

National Resilience, Inc. (Resilience), a technology focused manufacturing company dedicated to broadening access to complex medicines, announced the acquisition of SwiftScale…
Read More...

GlaxoSmithKline plc and Vir Biotechnology, Inc. announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation for…
Read More...

Valneva SE confirmed that the European Medicines Agency (EMA) has started a rolling review of VLA2001, its whole-virus inactivated, adjuvanted COVID-19 vaccine candidate. Valneva…
Read More...

Sanofi announced it entered into an agreement to acquire Origimm Biotechnology GmbH, an Austrian privately owned biotechnology company specializing in the discovery of virulent skin…
Read More...

Merck, known as MSD outside the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental Biologics License…
Read More...

Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company, announced that it is working with Pfizer to create innovative, cloud-based solutions with the potential to improve how new…
Read More...

Premas Biotech announced that its joint venture Oravax will initiate testing of their oral virus-like particle (VLP) vaccine candidate against Omicron variant of SARS-CoV 2 virus…
Read More...

Astellas Pharma Inc. and Dyno Therapeutics, Inc. announced an option and license agreement was signed on November 23 to develop next-generation adeno-associated virus (AAV) vectors for…
Read More...

AbbVie announced it has submitted an application to the European Medicines Agency (EMA) seeking approval for risankizumab (SKYRIZI, 600 mg intravenous (IV) induction and 360 mg…
Read More...

AstraZeneca’s supplemental New Drug Application (sNDA) for Lynparza (olaparib) has been accepted and granted Priority Review in the US for the adjuvant treatment of patients with…
Read More...

UCB, a global biopharmaceutical company, and Chiesi Group, the international research-focused pharmaceutical and healthcare group, are pleased to announce that they have entered into an…
Read More...

BONE THERAPEUTICS, the cell therapy company addressing unmet medical needs in orthopedics and other diseases, and Link Health Pharma Co., Ltd announce the signing of a non-binding term…
Read More...

As we have with previous emerging COVID-19 variants, the U.S. Food and Drug Administration is actively working with our federal partners, international regulators and medical product…
Read More...

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced…
Read More...

Kymera Therapeutics, Inc. a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced…
Read More...

Valneva SE and IDT Biologika announced their collaboration for the production of Valneva’s inactivated COVID-19 vaccine candidate VLA2001. This follows last week’s announcement that…
Read More...

Quell Therapeutics Ltd ("Quell"), the world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system,…
Read More...